Nothing Special   »   [go: up one dir, main page]

TN2016000040A1 - Inhibiteurs de porc2 et procedes pour leur utilisation - Google Patents

Inhibiteurs de porc2 et procedes pour leur utilisation

Info

Publication number
TN2016000040A1
TN2016000040A1 TN2016000040A TN2016000040A TN2016000040A1 TN 2016000040 A1 TN2016000040 A1 TN 2016000040A1 TN 2016000040 A TN2016000040 A TN 2016000040A TN 2016000040 A TN2016000040 A TN 2016000040A TN 2016000040 A1 TN2016000040 A1 TN 2016000040A1
Authority
TN
Tunisia
Prior art keywords
methods
porc2
inhibitors
pharmaceutical compositions
compounds
Prior art date
Application number
TN2016000040A
Other languages
English (en)
Inventor
James Blinn
Andrew Flick
Peter Jones
Neelu Kaila
James Kiefer
Ravi Kurumbail
Scot Mente
Marvin Meyers
Mark Schnute
Atli Thorarensen
Göran Wennerstål
Li Xing
Edouard Zamaratski
Christoph Zapf
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TN2016000040A1 publication Critical patent/TN2016000040A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention propose des composés, des compositions pharmaceutiques, des procédés d'inhibition de l'activité de RORy et/ou de réduction de la quantité de IL-17 chez un sujet, et des procédés de traitement de divers troubles médicaux au moyen de ces composés et compositions pharmaceutiques.
TN2016000040A 2013-08-02 2014-07-24 Inhibiteurs de porc2 et procedes pour leur utilisation TN2016000040A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361861709P 2013-08-02 2013-08-02
PCT/IB2014/063383 WO2015015378A2 (fr) 2013-08-02 2014-07-24 Inhibiteurs de rorc2 méthodes d'utilisation associées

Publications (1)

Publication Number Publication Date
TN2016000040A1 true TN2016000040A1 (fr) 2017-07-05

Family

ID=51570793

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2016000040A TN2016000040A1 (fr) 2013-08-02 2014-07-24 Inhibiteurs de porc2 et procedes pour leur utilisation

Country Status (42)

Country Link
US (6) US20160046597A1 (fr)
EP (2) EP3027603B1 (fr)
JP (1) JP6224832B2 (fr)
KR (1) KR101821903B1 (fr)
CN (1) CN105492434B (fr)
AP (1) AP2016009017A0 (fr)
AR (1) AR097199A1 (fr)
AU (1) AU2014298017B2 (fr)
BR (1) BR112016001781A2 (fr)
CA (1) CA2919783C (fr)
CL (1) CL2016000235A1 (fr)
CR (1) CR20160047A (fr)
CU (2) CU24398B1 (fr)
CY (1) CY1120751T1 (fr)
DK (1) DK3027603T3 (fr)
DO (1) DOP2016000039A (fr)
EA (1) EA029499B9 (fr)
EC (1) ECSP16008797A (fr)
ES (1) ES2685839T3 (fr)
GE (1) GEP20186876B (fr)
GT (1) GT201600027A (fr)
HK (1) HK1219093A1 (fr)
HR (1) HRP20181291T1 (fr)
HU (1) HUE039972T2 (fr)
IL (1) IL243728B (fr)
LT (1) LT3027603T (fr)
MA (1) MA38810B1 (fr)
MD (1) MD20160007A2 (fr)
MX (1) MX2016001446A (fr)
NI (1) NI201600021A (fr)
PE (1) PE20160801A1 (fr)
PH (1) PH12016500140A1 (fr)
PL (1) PL3027603T3 (fr)
PT (1) PT3027603T (fr)
RS (1) RS57618B1 (fr)
SG (1) SG11201600200QA (fr)
SI (1) SI3027603T1 (fr)
TN (1) TN2016000040A1 (fr)
TW (2) TW201516041A (fr)
UA (1) UA115908C2 (fr)
UY (1) UY35687A (fr)
WO (1) WO2015015378A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
CA2975157C (fr) * 2015-01-30 2019-09-17 Pfizer Inc. Modulateurs indole de rorc2 substitues par sulfonamide et leurs procedes d'utilisation
EP3250570A1 (fr) * 2015-01-30 2017-12-06 Pfizer Inc Modulateurs de pyrrolopyridine substituée par un méthoxy de rorc2 et leurs méthodes d'utilisation
CN104672121B (zh) * 2015-02-16 2017-10-24 上海华默西医药科技有限公司 2r‑(2,5‑二氟苯基)吡咯烷盐酸盐的制备方法
EP3307734B1 (fr) 2015-06-09 2019-11-27 AbbVie Inc. Modulateurs des récepteurs nucléaires (ror) pour le traitement des maladies inflammatoires et autoimmunes
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
CN109206401B (zh) * 2017-06-29 2021-03-05 南京柯菲平盛辉制药有限公司 一类甲基-1H-吲唑类RORγ调节剂及其用途
WO2019178079A1 (fr) * 2018-03-12 2019-09-19 Abbvie Inc. Inhibiteurs de la signalisation à médiation par la tyrosine kinase 2
CN114450274A (zh) 2019-07-11 2022-05-06 伊斯凯普生物公司 作为lrrk2抑制剂的吲唑及氮杂吲唑
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
EP4136068B1 (fr) * 2020-04-16 2024-07-10 Basf Se Procédé de préparation de chlorures 4-cyanobenzoyl

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742057A (en) * 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
HUP9800417A3 (en) * 1995-03-20 2001-04-28 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)-indoles and 5-substituted-3-(piperidin-4-yl)-1h-indoles, their use as new 5-ht agonists, pharmaceutical compositions containing these compounds
US5962473A (en) * 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
WO1998011895A1 (fr) * 1996-09-18 1998-03-26 Eli Lilly And Company Methode de prevention de migraine
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
JP2001512727A (ja) * 1997-08-09 2001-08-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ−１受容体のリガンドとしてのニ環式化合物
CA2319174A1 (fr) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Agents therapeutiques modulant les recepteurs 5-ht
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
MX2010009410A (es) * 2008-02-29 2010-11-30 Array Biopharma Inc Compuestos del inhibidor de raf y métodos de uso de los mismos.
EP2638014B1 (fr) * 2010-11-08 2017-01-04 Lycera Corporation Tétrahydroquinolines et composés bicycliques associés n-sulphonylées pour l'inhibition de l'activité rorgamma et le traitement de maladies
EP2511263A1 (fr) * 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Composés de pyrrolo sulfonamide pour la modulation d'activité de récepteur-gamma orphelin (gamme ROR, NR1F3) associée au RAR de récepteur nucléaire orphelin et pour le traitement des maladies inflammatoires et de maladies auto-immunes chroniques
WO2013064231A1 (fr) * 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag Sulfonamides à sept chaînons comme modulateurs des récepteurs gamma orphelins associés à un récepteur de l'acide rétinoïque (rorγ, nr1f3)
EA028330B1 (ru) * 2012-05-31 2017-11-30 Фенекс Фармасьютикалз Аг ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
WO2014026328A1 (fr) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés d'indazole et d'indole à substitution 3-cyclohexényle en tant qu'inhibiteurs de rorgammat et leurs utilisations
WO2013171729A2 (fr) * 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Composés d'aryl- et hétéroarylamide en tant que modulateur de rorγt

Also Published As

Publication number Publication date
PT3027603T (pt) 2018-10-11
JP2016528226A (ja) 2016-09-15
US20170233371A1 (en) 2017-08-17
AR097199A1 (es) 2016-02-24
WO2015015378A2 (fr) 2015-02-05
PH12016500140B1 (en) 2016-04-18
EA029499B1 (ru) 2018-04-30
TW201733998A (zh) 2017-10-01
CU20160015A7 (es) 2016-09-30
EA029499B9 (ru) 2018-07-31
CU24366B1 (es) 2018-10-04
KR20160037996A (ko) 2016-04-06
EP3428160A1 (fr) 2019-01-16
PE20160801A1 (es) 2016-08-24
US20180086736A1 (en) 2018-03-29
AU2014298017B2 (en) 2018-03-29
NI201600021A (es) 2016-03-16
PL3027603T3 (pl) 2019-03-29
GEP20186876B (en) 2018-07-10
DOP2016000039A (es) 2016-06-15
EP3027603B1 (fr) 2018-07-18
HUE039972T2 (hu) 2019-02-28
EP3027603A2 (fr) 2016-06-08
JP6224832B2 (ja) 2017-11-01
KR101821903B1 (ko) 2018-01-24
AP2016009017A0 (en) 2016-01-31
DK3027603T3 (en) 2018-09-17
CL2016000235A1 (es) 2017-07-07
US20180282304A1 (en) 2018-10-04
US20190144429A1 (en) 2019-05-16
HRP20181291T1 (hr) 2018-10-19
LT3027603T (lt) 2018-08-10
TW201516041A (zh) 2015-05-01
IL243728A0 (en) 2016-04-21
MA38810B1 (fr) 2018-06-29
CR20160047A (es) 2016-03-03
ES2685839T3 (es) 2018-10-11
MD20160007A2 (ro) 2016-06-30
SI3027603T1 (sl) 2018-10-30
PH12016500140A1 (en) 2016-04-18
TWI652263B (zh) 2019-03-01
HK1219093A1 (zh) 2017-03-24
US20200039960A1 (en) 2020-02-06
AU2014298017A1 (en) 2016-02-11
CA2919783C (fr) 2018-02-06
CA2919783A1 (fr) 2015-02-05
US20160046597A1 (en) 2016-02-18
GT201600027A (es) 2019-09-20
SG11201600200QA (en) 2016-02-26
IL243728B (en) 2018-10-31
CN105492434A (zh) 2016-04-13
UA115908C2 (uk) 2018-01-10
BR112016001781A2 (pt) 2017-08-01
MA38810A1 (fr) 2017-10-31
CY1120751T1 (el) 2019-12-11
CN105492434B (zh) 2018-02-16
EA201690039A1 (ru) 2016-08-31
WO2015015378A3 (fr) 2015-05-14
MX2016001446A (es) 2016-05-05
CU20160145A7 (es) 2017-02-02
CU24398B1 (es) 2019-04-04
ECSP16008797A (es) 2017-08-31
UY35687A (es) 2015-02-27
RS57618B1 (sr) 2018-11-30

Similar Documents

Publication Publication Date Title
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
PH12017501306A1 (en) Inhibitors of histone demethylases
MA41014B1 (fr) Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
TN2014000195A1 (fr) 2-thiopyrimidinones
EA201290677A1 (ru) Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения
EA201500362A1 (ru) Ингибиторы rho-киназы
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
PH12017500453A1 (en) Spirocyclic inhibitors of cathepsin c
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MA35716B1 (fr) Formulations pharmaceutiques
MA33457B1 (fr) L-sérine pour son utilisation en tant que médicament pour prévenir et/ou traiter une réaction inflammatoire de la peau
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
EA201690673A1 (ru) Комбинированная терапия лахинимодом для лечения рассеянного склероза
MA39719B1 (fr) Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز
MA39260A1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c